Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL HUMAN RABIES VACCINES MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL HUMAN RABIES VACCINES MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 PIPELINE CURVE
2.2.3 MARKET GUIDE
2.2.4 COMPANY POSITIONING GRID
2.2.5 COMPANY MARKET SHARE ANALYSIS
2.2.6 MULTIVARIATE MODELLING
2.2.7 TOP TO BOTTOM ANALYSIS
2.2.8 STANDARDS OF MEASUREMENT
2.2.9 VENDOR SHARE ANALYSIS
2.2.10 EPIDEMIOLOGY MODELLING
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL HUMAN RABIES VACCINES MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S 5 FORCES
6 EPIDEMIOLOGY
7 INDUSTRY INSIGHTS
8 REGULATORY FRAMEWORK
9 PIPELINE ANALYSIS
9.1 PHASE III CANDIDATES
9.2 PHASE II CANDIDATES
9.3 PHASE I CANDIDATES
9.4 OTHERS (PRE-CLINICAL AND RESEARCH)
10 GLOBAL HUMAN RABIES VACCINES MARKET, BY CELL LINE TYPE
10.1 OVERVIEW
10.2 MARKETED
10.2.1 HUMAN DIPLOID CELL VACCINE (HDCV)
10.2.2 PURIFIED CHICK EMBRYO CELL VACCINE (PCECV)
10.2.3 PURIFIED VERO CELL VACCINE (PVRV)
10.2.4 BABY HAMSTER KIDNEY (BHK) CELLS
10.2.5 OTHER
10.3 PIPLINE/EMERGING
10.3.1 PROTEIN VACCINES
10.3.2 ADJUVANTED RABIES VACCINES
10.3.3 GENETIC VACCINES
10.3.4 RNA VACCINES
10.3.5 DNA VACCINES
10.3.6 VIRAL VECTOR VACCINES
11 GLOBAL HUMAN RABIES VACCINES MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 PRE EXPOSURE PROPHYLAXIS
11.3 POST EXPOSURE PROPHYLAXIS
12 GLOBAL HUMAN RABIES VACCINES MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 INTRAMUSCULAR
12.3 INTRADERMAL
13 GLOBAL HUMAN RABIES VACCINES MARKET, BY BRAND
13.1 OVERVIEW
13.2 IMOVAX RABIES
13.3 RABAVERT
13.4 ABHAYRAB
13.5 BERIRAB-P
13.6 CARIG
13.7 EQUIRAB
13.8 OTHER
14 GLOBAL HUMAN RABIES VACCINES MARKET, BY POPULATION TYPE
14.1 OVERVIEW
14.2 PEDIATRIC
14.3 ADULT
15 GLOBAL HUMAN RABIES VACCINES MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.2.1 PRIVATE
15.2.2 PUBLIC
15.3 SPECIALITY CLINICS
15.4 COMMUNITY CENTER
15.5 OTHER
16 GLOBAL HUMAN RABIES VACCINES MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDERS
16.3 RETAILS PHARMACIES
16.4 ONLINE PHARMACIES
16.5 OTHERS
17 GLOBAL HUMAN RABIES VACCINES MARKET, BY GEOGRAPHY
17.1 GLOBAL HUMAN RABIES VACCINES MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
17.2 NORTH AMERICA
17.2.1 U.S.
17.2.2 CANADA
17.2.3 MEXICO
17.3 EUROPE
17.3.1 GERMANY
17.3.2 U.K.
17.3.3 ITALY
17.3.4 FRANCE
17.3.5 SPAIN
17.3.6 RUSSIA
17.3.7 SWITZERLAND
17.3.8 TURKEY
17.3.9 BELGIUM
17.3.10 NETHERLANDS
17.3.11 DENMARK
17.3.12 SWEDEN
17.3.13 POLAND
17.3.14 NORWAY
17.3.15 FINLAND
17.3.16 REST OF EUROPE
17.4 ASIA-PACIFIC
17.4.1 JAPAN
17.4.2 CHINA
17.4.3 SOUTH KOREA
17.4.4 INDIA
17.4.5 SINGAPORE
17.4.6 THAILAND
17.4.7 INDONESIA
17.4.8 MALAYSIA
17.4.9 PHILIPPINES
17.4.10 AUSTRALIA
17.4.11 NEW ZEALAND
17.4.12 VIETNAM
17.4.13 TAIWAN
17.4.14 REST OF ASIA-PACIFIC
17.5 SOUTH AMERICA
17.5.1 BRAZIL
17.5.2 ARGENTINA
17.5.3 REST OF SOUTH AMERICA
17.6 MIDDLE EAST AND AFRICA
17.6.1 SOUTH AFRICA
17.6.2 EGYPT
17.6.3 BAHRAIN
17.6.4 UNITED ARAB EMIRATES
17.6.5 KUWAIT
17.6.6 OMAN
17.6.7 QATAR
17.6.8 SAUDI ARABIA
17.6.9 REST OF MEA
18 COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: GLOBAL
18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
18.3 COMPANY SHARE ANALYSIS: EUROPE
18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
18.5 MERGERS & ACQUISITIONS
18.6 NEW PRODUCT DEVELOPMENT & APPROVALS
18.7 EXPANSIONS
18.8 REGULATORY CHANGES
18.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
19 GLOBAL HUMAN RABIES VACCINES MARKET, SWOT AND DBMR ANALYSIS
20 GLOBAL HUMAN RABIES VACCINES MARKET, COMPANY PROFILE
20.1 BHARAT BIOTECH
20.1.1 COMPANY OVERVIEW
20.1.2 REVENUE ANALYSIS
20.1.3 GEOGRAPHIC PRESENCE
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENTS
20.2 SERUM INSTITUTE OF INDIA PVT. LTD.
20.2.1 COMPANY OVERVIEW
20.2.2 REVENUE ANALYSIS
20.2.3 GEOGRAPHIC PRESENCE
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENTS
20.3 NOVARTIS AG
20.3.1 COMPANY OVERVIEW
20.3.2 REVENUE ANALYSIS
20.3.3 GEOGRAPHIC PRESENCE
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENTS
20.4 CADILA PHARMACEUTICALS.
20.4.1 COMPANY OVERVIEW
20.4.2 REVENUE ANALYSIS
20.4.3 GEOGRAPHIC PRESENCE
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENTS
20.5 MERCK & CO., INC.
20.5.1 COMPANY OVERVIEW
20.5.2 REVENUE ANALYSIS
20.5.3 GEOGRAPHIC PRESENCE
20.5.4 PRODUCT PORTFOLIO
20.5.5 RECENT DEVELOPMENTS
20.6 SANOFI
20.6.1 COMPANY OVERVIEW
20.6.2 REVENUE ANALYSIS
20.6.3 GEOGRAPHIC PRESENCE
20.6.4 PRODUCT PORTFOLIO
20.6.5 RECENT DEVELOPMENTS
20.7 GSK PLC
20.7.1 COMPANY OVERVIEW
20.7.2 REVENUE ANALYSIS
20.7.3 GEOGRAPHIC PRESENCE
20.7.4 PRODUCT PORTFOLIO
20.7.5 RECENT DEVELOPMENTS
20.8 BERNA BIOTECH PHARMA GMBH
20.8.1 COMPANY OVERVIEW
20.8.2 REVENUE ANALYSIS
20.8.3 GEOGRAPHIC PRESENCE
20.8.4 PRODUCT PORTFOLIO
20.8.5 RECENT DEVELOPMENTS
20.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH.
20.9.1 COMPANY OVERVIEW
20.9.2 REVENUE ANALYSIS
20.9.3 GEOGRAPHIC PRESENCE
20.9.4 PRODUCT PORTFOLIO
20.9.5 RECENT DEVELOPMENTS
20.1 BIO-MED
20.10.1 COMPANY OVERVIEW
20.10.2 REVENUE ANALYSIS
20.10.3 GEOGRAPHIC PRESENCE
20.10.4 PRODUCT PORTFOLIO
20.10.5 RECENT DEVELOPMENTS
20.11 INDIAN IMMUNOLOGICALS LTD
20.11.1 COMPANY OVERVIEW
20.11.2 REVENUE ANALYSIS
20.11.3 GEOGRAPHIC PRESENCE
20.11.4 PRODUCT PORTFOLIO
20.11.5 RECENT DEVELOPMENTS
20.12 KEDRION BIOPHARMA
20.12.1 COMPANY OVERVIEW
20.12.2 REVENUE ANALYSIS
20.12.3 GEOGRAPHIC PRESENCE
20.12.4 PRODUCT PORTFOLIO
20.12.5 RECENT DEVELOPMENTS
20.13 GRIFOLS, S.A.
20.13.1 COMPANY OVERVIEW
20.13.2 REVENUE ANALYSIS
20.13.3 GEOGRAPHIC PRESENCE
20.13.4 PRODUCT PORTFOLIO
20.13.5 RECENT DEVELOPMENTS
20.14 BAVARIAN NORDIC
20.14.1 COMPANY OVERVIEW
20.14.2 REVENUE ANALYSIS
20.14.3 GEOGRAPHIC PRESENCE
20.14.4 PRODUCT PORTFOLIO
20.14.5 RECENT DEVELOPMENTS
20.15 KAMADA PHARMACEUTICALS
20.15.1 COMPANY OVERVIEW
20.15.2 REVENUE ANALYSIS
20.15.3 GEOGRAPHIC PRESENCE
20.15.4 PRODUCT PORTFOLIO
20.15.5 RECENT DEVELOPMENTS
20.16 CHIRON BEHRING PVT. LTD.
20.16.1 COMPANY OVERVIEW
20.16.2 REVENUE ANALYSIS
20.16.3 GEOGRAPHIC PRESENCE
20.16.4 PRODUCT PORTFOLIO
20.16.5 RECENT DEVELOPMENTS
20.17 ZUVENTUS HEALTHCARE LTD
20.17.1 COMPANY OVERVIEW
20.17.2 REVENUE ANALYSIS
20.17.3 GEOGRAPHIC PRESENCE
20.17.4 PRODUCT PORTFOLIO
20.17.5 RECENT DEVELOPMENTS
*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
21 RELATED REPORTS
22 CONCLUSION
23 QUESTIONNAIRE
24 ABOUT DATA BRIDGE MARKET RESEARCH
